Browsing by author "Popat, Sanjay"
Now showing items 1-20 of 52
-
Addressing challenges with real-world synthetic control arms to demonstrate the comparative effectiveness of Pralsetinib in non-small cell lung cancer.
Popat, S; Liu, SV; Scheuer, N; Hsu, GG; Lockhart, A; et al. (NATURE PORTFOLIO, 2022-06-17)As advanced non-small cell lung cancer (aNSCLC) is being increasingly divided into rare oncogene-driven subsets, conducting randomised trials becomes challenging. Using real-world data (RWD) to construct control arms for ... -
Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: An Updated Database of 1023 Cases Brief Report.
Yang, JC-H; Schuler, M; Popat, S; Miura, S; Park, K; et al. (FRONTIERS MEDIA SA, 2022-04-28)Introduction: Previously, we developed a database of 693 patients with NSCLC and uncommon EGFR mutations treated with afatinib. Here, we provide an update of >1000 patients, with more data on specific mutations. Methods: ... -
Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases.
Yang, JC-H; Schuler, M; Popat, S; Miura, S; Heeke, S; et al. (ELSEVIER SCIENCE INC, 2020-05-01)INTRODUCTION: Limited clinical data are available regarding the efficacy of EGFR tyrosine kinase inhibitors (EGFR TKIs) in patients with NSCLC harboring uncommon EGFR mutations. This pooled analysis assessed the activity ... -
Amivantamab Compared with Real-World Physician's Choice after Platinum-Based Therapy from a Pan-European Chart Review of Patients with Lung Cancer and Activating EGFR Exon 20 Insertion Mutations.
Christopoulos, P; Girard, N; Proto, C; Soares, M; Lopez, PG; et al. (MDPI, 2023-11-08)Patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor gene (EGFR) Exon 20 insertions (Exon20ins) at the second line and beyond (2L+) have an unmet need for new treatment. Amivantamab, ... -
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.
Passaro, A; Wang, J; Wang, Y; Lee, S-H; Melosky, B; et al. (ELSEVIER, 2023-10-23)BACKGROUND: Amivantamab plus carboplatin-pemetrexed (chemotherapy) with and without lazertinib demonstrated antitumor activity in patients with refractory epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell ... -
Anti-angiogenic agents in the age of resistance to immune checkpoint inhibitors: Do they have a role in non-oncogene-addicted non-small cell lung cancer?
Popat, S; Grohé, C; Corral, J; Reck, M; Novello, S; et al. (ELSEVIER IRELAND LTD, 2020-06-01)The introduction of licensed front-line immunotherapies has heralded a new era for the treatment of non-oncogene-addicted, advanced non-small cell lung cancer (NSCLC). Yet as with all evolutions in clinical management, ... -
Association Between Smoking History and Overall Survival in Patients Receiving Pembrolizumab for First-Line Treatment of Advanced Non-Small Cell Lung Cancer.
Popat, S; Liu, SV; Scheuer, N; Gupta, A; Hsu, GG; et al. (AMER MEDICAL ASSOC, 2022-05-02)Importance: There is a need to tailor treatments to patients who are most likely to derive the greatest benefit from them to improve patient outcomes and enhance cost-effectiveness of cancer therapies. Objective: To compare ... -
Biomarker Testing for People With Advanced Lung Cancer in England.
Adizie, JB; Tweedie, J; Khakwani, A; Peach, E; Hubbard, R; et al. (ELSEVIER, 2021-06-01)INTRODUCTION: Optimal management of people with advanced NSCLC depends on accurate identification of predictive markers. Yet, real-world data in this setting are limited. We describe the impact, timeliness, and outcomes ... -
Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial.
Yang, JC-H; Liu, G; Lu, S; He, J; Burotto, M; et al. (ELSEVIER SCIENCE INC, 2023-08-12)INTRODUCTION: This open-label, phase 3 trial (ALTA-3; NCT03596866) compared efficacy and safety of brigatinib versus alectinib for ALK+ NSCLC after disease progression on crizotinib. METHODS: Patients with advanced ALK+ ... -
Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial.
Camidge, DR; Kim, HR; Ahn, M-J; Yang, JCH; Han, J-Y; et al. (AMER SOC CLINICAL ONCOLOGY, 2020-11-01)PURPOSE: Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor, demonstrated superior progression-free survival (PFS) and improved health-related quality of life (QoL) versus crizotinib in advanced ALK ... -
Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial.
Camidge, DR; Kim, HR; Ahn, M-J; Yang, JCH; Han, J-Y; et al. (2021-09-16)Introduction In the phase 3 study entitled ALK in Lung cancer Trial of brigAtinib in 1st Line (ALTA-1L), which is a study of brigatinib in ALK inhibitor-naive advanced ALK-positive NSCLC, brigatinib exhibited superior ... -
Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.
Camidge, DR; Kim, HR; Ahn, M-J; Yang, JC-H; Han, J-Y; et al. (2018-11)Background Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor, has robust efficacy in patients with ALK-positive non-small-cell lung cancer (NSCLC) that is refractory to crizotinib. The efficacy of ... -
Brigatinib vs alectinib in crizotinib-resistant advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALTA-3).
Popat, S; Liu, G; Lu, S; Song, G; Ma, X; et al.Crizotinib is highly efficacious and more tolerable than chemotherapy for ALK<sup>+</sup> non-small-cell lung cancer (NSCLC), but its progression-free survival benefit and intracranial efficacy have limitations. Head-to-head ... -
Challenges and controversies in resectable non-small cell lung cancer: a clinician's perspective.
Houda, I; Dickhoff, C; Uyl-de Groot, CA; Damhuis, RAM; Reguart, N; et al. (ELSEVIER, 2024-03-01)The treatment landscape of resectable early-stage non-small cell lung cancer (NSCLC) is transforming due to the approval of novel adjuvant and neoadjuvant systemic treatments. The European Medicines Agency (EMA) recently ... -
Crizotinib-Resistant ROS1 G2101A Mutation Associated With Sensitivity to Lorlatinib in ROS1-Rearranged NSCLC: Case Report.
Begum, P; Cui, W; Popat, S (ELSEVIER, 2022-09-01)gene rearrangements occur in 1% to 2% of NSCLC. Acquired "on-target" mutations within the ROS1 kinase domain are a known resistance mechanism to the first-line ROS1 inhibitor crizotinib. Here, we report the first case of ... -
Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?
Reck, M; Kerr, KM; Grohé, C; Manegold, C; Pavlakis, N; et al. (2019-04)A substantial proportion of patients with nononcogene-addicted non-small-cell lung cancer (NSCLC) has 'aggressive disease', as reflected in short time to progression or lack of disease control with initial platinum-based ... -
A definitive prognostication system for patients with thoracic malignancies diagnosed with COVID-19: an update from the TERAVOLT registry.
Whisenant, JG; Baena, J; Cortellini, A; Huang, L-C; Lo Russo, G; et al. (2022-01-24)<h4>Background</h4>Patients with thoracic malignancies are at increased risk for mortality from Coronavirus disease 2019 (COVID-19) and large number of intertwined prognostic variables have been identified so far.<h4>Met ... -
Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries.
de Jager, VD; Timens, W; Bayle, A; Botling, J; Brcic, L; et al. (ELSEVIER, 2024-03-01)In the past two decades, the treatment of metastatic non-small cell lung cancer (NSCLC), has undergone significant changes due to the introduction of targeted therapies and immunotherapy. These advancements have led to the ... -
Discordance in Recommendation Between Next-Generation Sequencing Test Reports and Molecular Tumor Boards in India.
Mathew, A; Davis, S; Boby, JM; R I, A; Suryavanshi, M; et al. (LIPPINCOTT WILLIAMS & WILKINS, 2024-03-01)PURPOSE: Accurate understanding of the genomic and transcriptomic data provided by next-generation sequencing (NGS) is essential for the effective utilization of precision oncology. Molecular tumor boards (MTBs) aim to ... -
Effectiveness and safety of immunotherapy in NSCLC patients with ECOG PS score ≥2 - Systematic review and meta-analysis.
Tomasik, B; Bieńkowski, M; Braun, M; Popat, S; Dziadziuszko, RBackground Immune checkpoint inhibitors (ICIs) are standard of care in advanced non-small cell lung cancer (NSCLC), however their status in patients with poor performance status (PS) is poorly defined. We aimed to evaluate ...